Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Board/Management Information 2012

Jun 26, 2012

31523_rns_2012-06-26_f8a0e2e8-bc9c-4434-85cf-bfe151d3aa3d.zip

Board/Management Information

Open in viewer

Opens in your device viewer

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): June 20, 2012

*AMICUS THERAPEUTICS, INC.*

(Exact name of registrant as specified in its charter)

Delaware 001-33497 71-0869350
(State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1 Cedar Brook Drive, Cranbury, NJ 08512
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\107534\12-15396-1\task5411091\15396-1-ba.htm',USER='107534',CD='Jun 26 05:04 2012'

*Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.*

(d) On June 20, 2012, Robert Essner was elected to the Board of Directors of Amicus Therapeutics, Inc. (the “Company”) as a Class I director. Mr. Essner joins the Board of Directors as an independent director and is expected to serve on the Audit Committee.

There is no arrangement or understanding between Mr. Essner and any other person pursuant to which Mr. Essner was elected as director of the Company. There are no relationships or transactions in which Mr. Essner has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\107534\12-15396-1\task5411091\15396-1-ba.htm',USER='107534',CD='Jun 26 05:04 2012'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMICUS THERAPEUTICS, INC. — By: /s/ PETER M. MACALUSO
Name: Peter M. Macaluso
Title: Secretary

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\107534\12-15396-1\task5411091\15396-1-ba.htm',USER='107534',CD='Jun 26 05:04 2012'